Jaguar Animal Health (JAGX) AI Stock Analysis

• Market Cap: $2.52M
• Dividend Yield: N/A
• Average Volume (3M): 7.21M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.06
• Revenue Growth: 12.45%
• EPS Growth: -544.23%
• Country: US
• Employees: 49
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -6.28
• Shares Outstanding: 3,735,837
• 10 Day Avg. Volume: 18,095,745
• 30 Day Avg. Volume: 7,210,530
• PEG Ratio: <0.01
• Price to Book (P/B): 1.02
• Price to Sales (P/S): 0.64
• P/FCF Ratio: -0.25
• Enterprise Value/Market Cap: 11.82
• Enterprise Value/Revenue: 2.53
• Enterprise Value/Gross Profit: 3.28
• Enterprise Value/Ebitda: -0.72
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $0.66 ▼(-48.59% Downside)

The score is held down primarily by weak financial performance (large ongoing losses, high leverage, and heavy cash burn) and a bearish technical setup (trading below all major moving averages with negative MACD). Corporate events provide a meaningful positive offset via non-dilutive funding and encouraging clinical progress, but not enough to overcome current financial and trend risks.

Positive Factors

High gross margins (~77% TTM)

Sustained ~77% gross margins indicate powerful unit economics for product sales. This margin profile can support investment in R&D and commercialization, absorb price or channel pressures, and materially improve profitability if fixed operating losses are reduced or revenue scales.

Progress in crofelemer rare‑disease program

Meaningful clinical and regulatory progress (FDA engagement, amended protocol and supportive PoC data) creates a credible pathway to orphan approvals. Orphan indications can command premium pricing with small patient populations, offering a durable route to high‑margin, specialty revenue if trials confirm benefit.

Non‑equity licensing deal with upfront cash

An $18M upfront licensing payment plus milestones provides material non‑dilutive liquidity and shifts commercialization burden to a partner while Jaguar retains manufacturing and reacquisition optionality. This structure strengthens near‑term funding and preserves upside if clinical indications advance.

Negative Factors

Heavy operating cash burn

Persistent ~-$26M TTM cash burn is a structural drain that forces reliance on external financing or partnerships. Over 2–6 months this constrains ability to fund trials/commercial expansion, increases dilution risk, and may force unfavorable financing terms or asset sales absent material revenue or deal milestones.

High leverage and thin equity cushion

Debt roughly 5.7x equity signals a fragile balance sheet and elevated refinancing or covenant risk. High leverage limits strategic flexibility, raises financing costs, and increases the probability of dilution or restrictive covenants that can hamper R&D or commercialization decisions over the medium term.

Falling revenue and very large net losses

A ~21% TTM revenue decline alongside deeply negative margins (~-342%) shows the business hasn't reached scalable commercial traction. Even with high gross margins, operating expenses far exceed sales; without durable revenue recovery or partner income, ongoing losses threaten long‑term self‑funding and increase dilution risk.

Jaguar Animal Health Business Overview & Revenue Model

Company Description

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.

How the Company Makes Money

Jaguar Animal Health generates revenue primarily through the sale of its pharmaceutical products and veterinary therapeutics. The company has established a revenue model that includes direct sales to veterinarians and animal health distributors, as well as partnerships with larger pharmaceutical companies for product development and distribution. Key revenue streams include prescription medications and potential royalties from collaborations. Additionally, Jaguar may engage in licensing agreements for its proprietary technologies, further enhancing its financial performance. Significant partnerships with veterinary practices and discussions with animal food companies also contribute to its earnings, as they help broaden the reach and application of its products in the market.

Jaguar Animal Health Financial Statement Overview

Summary

Very weak fundamentals: revenue declined (~21% TTM), losses are extremely large relative to revenue (net margin ~-342% TTM), leverage is high (~5.7x debt-to-equity with a thin equity base), and operating/free cash flow remain deeply negative (about -$26M TTM). High gross margin (~77% TTM) is a notable but insufficient offset.

Income Statement

TTM (Trailing-Twelve-Months) revenue declined about 21% versus the prior period, following uneven growth in recent years. Gross margins remain very strong (about 77% TTM), but the company is still deeply unprofitable: operating losses and net losses are multiple times revenue (net margin around -342% TTM), with losses remaining broadly elevated across 2020–TTM. Strength is primarily the high gross margin profile; weakness is persistent, very large operating losses with no clear improvement in profitability.

Balance Sheet

Leverage is high: total debt is about $31.9M TTM versus equity of about $5.6M, implying roughly 5.7x debt-to-equity (also elevated in prior years). Equity has been thin and even turned negative in 2022, underscoring balance-sheet fragility. Total assets are relatively stable (~$49.5M TTM), but returns to shareholders are sharply negative due to ongoing losses. Strength: assets have not collapsed; weakness: high leverage and limited equity cushion increase financing and dilution risk.

Cash Flow

Cash burn remains heavy: operating cash flow is about -$26.0M TTM and free cash flow about -$26.1M, with free cash flow deteriorating sharply versus the prior year. While cash burn improved modestly from 2023–2024 levels, the business is still materially consuming cash rather than generating it, and cash flow does not yet indicate a self-funding trajectory. Strength: some reduction in burn versus prior years; weakness: persistently negative operating and free cash flow with volatile trends.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	11.79M	11.69M	9.76M	11.96M	4.33M	9.38M
Gross Profit	9.09M	9.73M	7.72M	9.94M	2.00M	6.11M
EBITDA	-41.16M	-36.66M	-32.76M	-33.38M	-42.37M	-28.74M
Net Income	-40.29M	-38.49M	-41.30M	-47.45M	-52.59M	-33.81M
Balance Sheet
Total Assets	49.47M	53.42M	50.76M	47.45M	53.27M	42.84M
Cash, Cash Equivalents and Short-Term Investments	3.53M	8.00M	6.47M	5.47M	17.05M	8.09M
Total Debt	31.90M	36.53M	37.09M	34.84M	29.36M	16.21M
Total Liabilities	45.11M	46.93M	45.87M	48.81M	41.41M	25.64M
Stockholders Equity	5.63M	7.29M	4.96M	-657.00K	11.61M	17.20M
Cash Flow
Free Cash Flow	-26.08M	-29.61M	-33.24M	-34.78M	-34.98M	-15.29M
Operating Cash Flow	-26.02M	-29.38M	-33.24M	-33.10M	-34.97M	-15.28M
Investing Cash Flow	-269.00K	-231.00K	0.00	-1.68M	-6.00K	-7.00K
Financing Cash Flow	16.71M	31.20M	34.23M	23.18M	43.94M	19.49M

Jaguar Animal Health Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.28
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JAGX, the sentiment is Negative. The current price of 1.28 is above the 20-day moving average (MA) of 0.89, above the 50-day MA of 1.09, and below the 200-day MA of 2.84, indicating a bearish trend. The MACD of -0.12 indicates Positive momentum. The RSI at 40.72 is Neutral, neither overbought nor oversold. The STOCH value of 2.16 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JAGX.

Jaguar Animal Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DRMA	47 Neutral	$7.15M	-0.14	-203.36%	―	―	90.53%
SXTP	46 Neutral	$5.50M	-0.17	-152.19%	―	192.72%	83.61%
JAGX	45 Neutral	$2.52M	-0.02	-370.95%	―	12.45%	-544.23%
REVB	45 Neutral	$3.31M	-0.02	-118.88%	―	―	96.26%
GLMD	44 Neutral	$4.45M	-0.21	-46.34%	―	―	70.71%
SNGX	43 Neutral	$13.82M	-0.36	-169.32%	―	―	53.13%

Jaguar Animal Health Corporate Events

Jaguar Health Executes Debt-Reducing Equity Warrant Transactions

On January 16, 2026, Jaguar Health executed a series of privately negotiated exchanges with Iliad Research and Trading and Streeterville Capital that reduced outstanding royalty interests and retired portions of its Series L and Series M perpetual preferred stock in return for issuing multiple pre-funded common stock purchase warrants. The transactions cut $1.19 million from an October 2020 royalty interest and $850,000 from an August 2022 royalty interest, and cancelled specified Series L and Series M preferred shares held by the two investors, while creating new pre-funded warrants exercisable at a nominal price and subject to a 9.99% ownership cap, effectively deleveraging the balance sheet at the cost of potential future equity dilution for existing shareholders.

The most recent analyst rating on (JAGX) stock is a Hold with a $0.82 price target. To see the full list of analyst forecasts on Jaguar Animal Health stock, see the JAGX Stock Forecast page.

Jaguar Animal Health Grants U.S. Rights to Crofelemer Drugs

On January 12, 2026, Jaguar Health’s subsidiary Napo Pharmaceuticals entered into a U.S. licensing and supply arrangement with Woodward Specialty, an affiliate of Future Pak, under which Future Pak becomes the exclusive U.S. marketer of Jaguar’s crofelemer-based drugs Mytesi and Canalevia-CA1, while Jaguar retains responsibility for manufacturing and supplying the products. The deal provides Jaguar with an $18 million upfront payment and up to $20 million in additional milestone and future payments, backed by limited guarantees from Future Pak, and gives Napo a time-limited option to reacquire U.S. rights to the products if additional crofelemer indications in the same formulation secure U.S. regulatory approval after a specified period; collectively, the structure delivers meaningful non-dilutive capital, simplifies Jaguar’s commercial operations in HIV supportive care and veterinary GI markets, and allows the company to sharpen its strategic focus on advancing crofelemer for rare intestinal failure indications while leveraging Future Pak’s established HIV-focused commercial infrastructure.

The most recent analyst rating on (JAGX) stock is a Hold with a $0.73 price target. To see the full list of analyst forecasts on Jaguar Animal Health stock, see the JAGX Stock Forecast page.

Jaguar Animal Health Raises Short-Term Capital Through Notes

On January 6, 2026, Jaguar Health, Inc. entered into securities purchase agreements with two accredited investors and closed a financing in which it issued $350,000 in unsecured promissory notes bearing 6% annual interest and maturing one month after issuance, with proceeds allocated to working capital and other general corporate purposes. As part of the transaction, the investors also received warrants to purchase up to 350,000 shares of Jaguar’s common stock at an initial exercise price of $1.00 per share, exercisable immediately and expiring upon the earlier of five years, a fundamental transaction, or a liquidation event; the deal was executed as a private placement exempt from SEC registration, reinforcing the company’s near-term liquidity but also modestly increasing potential future equity dilution for existing shareholders.

The most recent analyst rating on (JAGX) stock is a Sell with a $0.93 price target. To see the full list of analyst forecasts on Jaguar Animal Health stock, see the JAGX Stock Forecast page.

Jaguar Health Executes Strategic Stock Exchange Agreements

On June 27, 2025, Jaguar Health, Inc. engaged in a transaction with Iliad Research and Trading, L.P., issuing 170 shares of Series M Perpetual Preferred Stock. Later, on December 9 and December 11, 2025, Jaguar Health entered into two separate exchange agreements with Iliad, resulting in the issuance of a total of 440,000 shares of common stock and pre-funded warrants to purchase 1,609,372 shares in exchange for 91 shares of Series M Preferred Stock, which were subsequently cancelled. These transactions reflect strategic financial maneuvers by Jaguar Health to manage its stock and capital structure, potentially impacting its market positioning and shareholder dynamics.

The most recent analyst rating on (JAGX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Jaguar Animal Health stock, see the JAGX Stock Forecast page.

Jaguar Health Announces Promising Trial Results for Crofelemer

On December 8, 2025, Jaguar Health held a Special Meeting where stockholders approved three proposals, including the issuance of new shares and potential meeting adjournments. The company also announced promising initial results from a trial of crofelemer for infants with microvillus inclusion disease, highlighting its potential to reduce parenteral support needs. This development, alongside a recent FDA meeting, suggests a possible expedited approval pathway, impacting Jaguar’s market positioning and stakeholder interests.

The most recent analyst rating on (JAGX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Jaguar Animal Health stock, see the JAGX Stock Forecast page.

Jaguar Health Amends Royalty Interests and Note Terms

On November 17, 2025, Jaguar Health, Inc. announced amendments to its royalty interests with Iliad Research and Trading, Uptown Capital, and Streeterville Capital, setting a minimum monthly royalty payment starting April 1, 2026. Additionally, the company extended the maturity date of a secured promissory note with Streeterville to April 1, 2026. In a separate exchange transaction, Jaguar Health issued common stock to Streeterville in exchange for preferred stock, which was then cancelled.

The most recent analyst rating on (JAGX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Jaguar Animal Health stock, see the JAGX Stock Forecast page.

Jaguar Animal Health Secures $10.8M Note Agreement

On November 12, 2025, Jaguar Health, Inc. entered into a note purchase agreement with Streeterville Capital, LLC, issuing a secured promissory note worth $10,810,000. The agreement includes an original issue discount and legal fees, with funds allocated to a newly formed subsidiary, JAGX Holdings, LLC. The note carries an 8% annual interest rate, with a 36-month maturity period, and includes provisions for mandatory prepayments and redemption rights. The company’s obligations are secured by various agreements, and certain covenants restrict Jaguar Health’s financial activities, ensuring compliance with the lender’s terms.

The most recent analyst rating on (JAGX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Jaguar Animal Health stock, see the JAGX Stock Forecast page.